GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ensol Biosciences Inc (XKRX:140610) » Definitions » Equity-to-Asset

Ensol Biosciences (XKRX:140610) Equity-to-Asset : -0.58 (As of Dec. 2023)


View and export this data going back to 2018. Start your Free Trial

What is Ensol Biosciences Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Ensol Biosciences's Total Stockholders Equity for the quarter that ended in Dec. 2023 was ₩-5,452.2 Mil. Ensol Biosciences's Total Assets for the quarter that ended in Dec. 2023 was ₩9,394.6 Mil. Therefore, Ensol Biosciences's Equity to Asset Ratio for the quarter that ended in Dec. 2023 was -0.58.

The historical rank and industry rank for Ensol Biosciences's Equity-to-Asset or its related term are showing as below:

XKRX:140610' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.58   Med: 0.21   Max: 0.91
Current: -0.58

During the past 10 years, the highest Equity to Asset Ratio of Ensol Biosciences was 0.91. The lowest was -0.58. And the median was 0.21.

XKRX:140610's Equity-to-Asset is ranked worse than
90.28% of 1554 companies
in the Biotechnology industry
Industry Median: 0.67 vs XKRX:140610: -0.58

Ensol Biosciences Equity-to-Asset Historical Data

The historical data trend for Ensol Biosciences's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ensol Biosciences Equity-to-Asset Chart

Ensol Biosciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Equity-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.13 -0.24 -0.12 -0.44 -0.58

Ensol Biosciences Semi-Annual Data
Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.13 -0.24 -0.12 -0.44 -0.58

Competitive Comparison of Ensol Biosciences's Equity-to-Asset

For the Biotechnology subindustry, Ensol Biosciences's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ensol Biosciences's Equity-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ensol Biosciences's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Ensol Biosciences's Equity-to-Asset falls into.



Ensol Biosciences Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Ensol Biosciences's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Equity to Asset (A: Dec. 2023 )=Total Stockholders Equity/Total Assets
=-5452.246/9394.57
=-0.58

Ensol Biosciences's Equity to Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

Equity to Asset (Q: Dec. 2023 )=Total Stockholders Equity/Total Assets
=-5452.246/9394.57
=-0.58

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Ensol Biosciences  (XKRX:140610) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


Ensol Biosciences Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Ensol Biosciences's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Ensol Biosciences (XKRX:140610) Business Description

Traded in Other Exchanges
N/A
Address
51, Techno 10-ro, Yuseong-gu, Daejeon, KOR, 34036
Ensol Biosciences Inc is a Korean big data-driven biopharmaceutical company. The company is engaged in developing drugs for the diseases that have no therapeutic alternatives, such as a degenerative disc, osteoarthritis, cancer, Alzheimer's dementia, and type 1 diabetes. Its drugs portfolio includes Peniel 2000 Drug for Degenerative Disc Disease, Engedi 1000 Drug for Osteoarthritis, Charis 1000 Drug for Immuno-Oncology, Moriah 1000 Drug for Alzheimer's Disease, Shiloah 1000 Drug for Type I Diabetes, and EAD100 Drug for Animal Osteoarthritis.

Ensol Biosciences (XKRX:140610) Headlines

No Headlines